

# DEXTROSE- dextrose monohydrate injection, solution

## Hospira, Inc.

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DEXTROSE INJECTION (25%) safely and effectively. See full prescribing information for DEXTROSE INJECTION (25%).

Initial U.S. Approval: 1940

### RECENT MAJOR CHANGES

Dosage and Administration (2.1, 2.2)	07/2025
Contraindications (4)	07/2025
Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6)	07/2025

### INDICATIONS AND USAGE

Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients younger than 2 years old. (1)

### DOSAGE AND ADMINISTRATION

- Only for intravenous infusion. Do not administer subcutaneously or intramuscularly. (2.1)
- The recommended initial dose is 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg). If clinically indicated, additional single doses of 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg) may be administered. (2.2)
- Infusion rate depends on the age, weight, and clinical and metabolic conditions of the patient and concomitant therapy. (2.2)
- See full prescribing information for more information on preparation, administration instructions, and dosing considerations. (2.1, 2.2)

### DOSAGE FORMS AND STRENGTHS

Injection:

25% (2.5 g/10 mL) (250 mg/mL) of dextrose hydrous in a clear, colorless solution in a single-dose Ansyr™ Plastic Syringe. (3)

### CONTRAINDICATIONS

- Intracranial or intraspinal hemorrhage. (4)
- Severe dehydration. (4)
- Hypersensitivity to dextrose. (4)

### WARNINGS AND PRECAUTIONS

- Hyperglycemia or Hyperosmolar Hyperglycemic State: Monitor blood glucose levels before and after treatment. Use caution when selecting the dosage and injection rate due to the increased risk of hyperglycemia in neonates and low birth weight infants. (5.1)
- Hypersensitivity Reactions: Monitor for signs and symptoms and discontinue infusion immediately if reaction occurs. (5.2)
- Phlebitis and Thrombosis: Remove catheter as soon as possible if thrombophlebitis develops. (2.1, 5.3)
- Electrolyte Imbalance and Fluid Overload: Monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during administration. (5.4)
- Hyponatremia: Monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and neurologic status. (5.5)
- Neonatal Adverse Reactions from Unapproved Maternal Use at Time of Delivery: Maternal hyperglycemia at the time of delivery has been associated with adverse outcomes such as neonatal hypoglycemia.

### ADVERSE REACTIONS

The most common adverse reactions are hyperglycemia, hypersensitivity reactions, hyponatremia,

infection (both systemic and at the injection site), vein thrombosis, phlebitis, and electrolyte imbalance.  
(6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Revised: 7/2025

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

### **2 DOSAGE AND ADMINISTRATION**

2.1 Important Preparation and Administration Instructions

2.2 Recommended Dosage

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State

5.2 Hypersensitivity Reactions

5.3 Phlebitis and Thrombosis

5.4 Electrolyte Imbalance and Fluid Overload

5.5 Hyponatremia

5.6 Neonatal Adverse Reactions from Unapproved Maternal Use at Time of Delivery

### **6 ADVERSE REACTIONS**

### **7 DRUG INTERACTIONS**

7.1 Drugs with Effects on Glycemic Control and Electrolyte Balance

### **8 USE IN SPECIFIC POPULATIONS**

8.4 Pediatric Use

### **10 OVERDOSAGE**

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients from birth up to 2 years of age.

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Important Preparation and Administration Instructions

- Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration. Do not use Dextrose Injection (25%) if the solution is cloudy or the seal has been broken.
- Obtain blood glucose level prior to administering Dextrose Injection (25%). However, in cases of emergency, administer Dextrose Injection (25%) promptly without awaiting blood glucose test results.
- Administer Dextrose Injection (25%) via slow intravenous injection into a central vein to reduce the risk of developing hyperglycemia and to minimize venous irritation [see *Warnings and Precautions* (5.1, 5.3)].
- Do not administer Dextrose Injection (25%) simultaneously with blood through the same infusion set because pseudoagglutination of red blood cells may occur.
- Administer Dextrose Injection (25%) intravenously. Do not administer Dextrose Injection (25%) subcutaneously or intramuscularly.
- Discard the unused portion.

### 2.2 Recommended Dosage

The recommended initial dose of Dextrose Injection (25%) is 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg). If clinically indicated, additional single doses of Dextrose Injection (25%) 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg) may be administered.

Select the appropriate infusion rate based on the age, weight, and clinical and metabolic conditions of the patient.

## 3 DOSAGE FORMS AND STRENGTHS

Injection:

- 25% (2.5 g/10 mL) (250 mg/mL) of dextrose hydrous, in a clear, colorless solution in a single-dose Ansyr™ Plastic Syringe

## 4 CONTRAINDICATIONS

Dextrose Injection (25%) is contraindicated in patients with:

- Intracranial or intraspinal hemorrhage because Dextrose Injection (25%) can worsen cerebral edema by causing a fluid shift across the blood-brain barrier.
- Severe dehydration because of the potential to worsen the patient's hyperosmolar state.
- Known hypersensitivity to dextrose [see *Warnings and Precautions* (5.2)].

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State

Significant hyperglycemia and hyperosmolar hyperglycemic state may result from too

rapid administration of Dextrose Injection (25%). Symptoms of hyperosmolar hyperglycemic state include mental confusion and loss of consciousness. To minimize these risks, slowly inject Dextrose Injection (25%) and monitor blood glucose levels before and after treatment with Dextrose Injection (25%).

Due to the increased risk of hyperglycemia in neonates and low birth weight infants, use caution when selecting the dosage and injection rate of Dextrose Injection (25%).

## **5.2 Hypersensitivity Reactions**

Hypersensitivity reactions, including anaphylaxis, have been reported with Dextrose Injection (25%) administration [see *Adverse Reactions (6)*]. Stop administration of Dextrose Injection (25%) immediately if signs or symptoms of a hypersensitivity reaction develop. Initiate appropriate treatment as clinically indicated.

## **5.3 Phlebitis and Thrombosis**

Dextrose Injection (25%) is hypertonic (has an osmolarity greater than 900 mOsm/L) and may cause phlebitis and thrombosis at the site of injection. If thrombophlebitis occurs, remove the catheter as soon as possible.

Administer Dextrose Injection (25%) via slow intravenous injection into a central vein to reduce the risk of phlebitis and thrombosis. Ensure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis occurs, stop administration of Dextrose Injection (25%) and initiate corrective measures. If central venous access cannot be obtained in these pediatric patients, consider using an alternative commercially available dextrose product with a lower concentration.

Do not administer Dextrose Injection (25%) subcutaneously or intramuscularly.

## **5.4 Electrolyte Imbalance and Fluid Overload**

Electrolyte deficits, particularly serum potassium and phosphate, may occur during prolonged use of Dextrose Injection (25%).

Depending on the administered volume and the infusion rate, administration of Dextrose Injection (25%) can cause fluid overload, including pulmonary edema.

Avoid Dextrose Injection (25%) in patients at risk for fluid and/or solute overload. If use cannot be avoided in these patients, monitor fluid balance, electrolyte concentrations, and acid base balance, especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration, and/or free water load.

## **5.5 Hyponatremia**

Dextrose Injection (25%) may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. The risk of hospital-acquired hyponatremia is increased in younger pediatric patients, and patients treated with diuretics, and patients with cardiac or pulmonary failure or with the syndrome of inappropriate antidiuretic hormone (SIADH) (e.g., postoperative patients, patients concomitantly treated with arginine vasopressin analogs or certain antiepileptic, psychotropic, and cytotoxic drugs) [see *Drug Interactions (7.1)* and *Use in Specific Populations (8.4)*].

Avoid Dextrose Injection (25%) in patients with or at risk for hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations, chloride concentrations, fluid status, acid-base balance, and neurologic status [see *Warnings and Precautions* (5.4)].

## **5.6 Neonatal Adverse Reactions from Unapproved Maternal Use at Time of Delivery**

Dextrose Injection (25%) is not approved for use in adolescents or adults. Maternal hyperglycemia secondary to the use of concentrated dextrose solutions at the time of delivery has been associated with adverse outcomes such as neonatal hypoglycemia.

## **6 ADVERSE REACTIONS**

The following clinically significant adverse reactions are also described elsewhere in the labeling:

- Hyperglycemia and Hyperosmolar Hyperglycemic State [see *Warnings and Precautions* (5.1)].
- Hypersensitivity Reactions [see *Warnings and Precautions* (5.2)].
- Phlebitis and Thrombosis [see *Warnings and Precautions* (5.3)]
- Electrolyte Imbalance and Fluid Overload [see *Warnings and Precautions* (5.4)]
- Hyponatremia [see *Warnings and Precautions* (5.5)]

The following adverse reactions associated with the use of Dextrose Injection were identified in clinical trials or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- *Administration site conditions:* blister, extravasation, phlebitis, erythema, pain, vein damage, thrombosis
- *Immune system disorders:* anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritis, pyrexia, rash
- *Cardiovascular disorders:* cyanosis, volume overload

## **7 DRUG INTERACTIONS**

### **7.1 Drugs with Effects on Glycemic Control and Electrolyte Balance**

Dextrose Injection (25%) can affect glycemic control, vasopressin, and fluid and/or electrolyte balance [see *Warnings and Precautions* (5.1, 5.4, 5.5)]. Monitor patients' blood glucose concentrations, fluid balance, serum electrolyte concentrations, and acid-base balance.

Concomitant administration of Dextrose Injection (25%) with drugs associated with hyponatremia may increase the risk of developing hyponatremia. Drugs associated with hyponatremia include diuretics and those that cause SIADH (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), arginine vasopressin analogs, certain antiepileptic, psychotropic, and cytotoxic drugs). Avoid use of Dextrose Injection (25%) in patients receiving drugs associated with hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations

during concomitant use [see *Warnings and Precautions* (5.5)].

## **8 USE IN SPECIFIC POPULATIONS**

### **8.4 Pediatric Use**

Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients from birth up to 2 years of age.

Dextrose Injection (25%) can increase the risk of developing hypo- or hyperglycemia in neonates, especially preterm neonates with low birth weight. Excessive or rapid administration of Dextrose Injection (25%) may also result in increased serum osmolality and increase the risk of intracerebral hemorrhage in very low birth weight neonates [see *Warnings and Precautions* (5.1)].

Monitor plasma electrolyte concentrations closely in pediatric patients who may have impaired ability to regulate fluids and electrolytes. Pediatric patients treated with Dextrose Injection (25%) are at increased risk of developing hyponatremia and hyponatremic encephalopathy [see *Warnings and Precautions* (5.4, 5.5)].

Dextrose Injection (25%) is not indicated in pediatric patients 2 years of age and older.


## **10 OVERDOSAGE**

A medication error resulting in a high infusion rate of Dextrose Injection (25%) can cause hyperglycemia, hyperosmolality, and adverse effects on fluid and electrolyte balance [see *Warnings and Precautions* (5.1, 5.4)].

Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal. In the event of overdosage (overhydration or solute overload) during Dextrose Injection (25%) treatment, discontinue the infusion. Institute corrective measures such as administration of exogenous insulin, and treat adverse effects on the CNS, respiratory, and cardiovascular systems [see *Warnings and Precautions* (5.1, 5.4)].

## **11 DESCRIPTION**

Dextrose, USP is chemically designated D-glucose monohydrate, ( $C_6H_{12}O_6 \cdot H_2O$ ), a hexose sugar freely soluble in water, with the following structural formula:



Water for Injection, USP is chemically designated H<sub>2</sub>O. The molecular weight of dextrose (D-glucose) monohydrate is 198.17.

Dextrose Injection, USP (25%) is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.

Each milliliter (mL) of fluid contains 0.25 grams of dextrose, hydrous, which delivers 3.4 kcal/gram (0.85 kcal/mL). The solution has an osmolarity of 1.39 mOsmol/mL (calculation) and the pH range is 3.2 to 6.5. May contain hydrochloric acid and sodium hydroxide for pH adjustment.

The solution contains no bacteriostatic, antimicrobial agent or added buffer (except for pH adjustment) and is supplied in a single-dose Ansyr™ Plastic Syringe.

Dextrose is derived from corn.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Dextrose restores blood glucose levels and provides a source of carbohydrate calories.

### 12.2 Pharmacodynamics

The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of dextrose have not been fully characterized.

### 12.3 Pharmacokinetics

Dextrose is oxidized to carbon dioxide and water.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies with dextrose to evaluate the drug's carcinogenic potential, mutagenic potential or effects on fertility have not been performed.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### How Supplied

Dextrose Injection, USP (25%) is supplied as a clear, colorless solution in single-dose syringe as follows:

Unit of Sale	Concentration
<b>NDC 0409-1775-10</b> Bundle of 10 Ansyr™ Plastic Syringes	25% (2.5 g/10 mL) (250 mg/mL)

### Storage and Handling

Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature.]

To contact Pfizer's Medical Information Department, please visit [www.pfizermedinfo.com](http://www.pfizermedinfo.com) or call 1-800-438-1985.

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

LAB-1057-5.0

### **PRINCIPAL DISPLAY PANEL - 10 mL Syringe Label**

10 mL Single-dose

Rx only

NDC 0409-1775-10

25% DEXTROSE Injection, USP

2.5 g/10 mL (250 mg/mL)


Usual Dosage: For intravenous use. See insert. Sterile, nonpyrogenic. 1.39 mOsmol/mL (calc.). pH is 4.5 (3.2 to 6.5).

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

Hospira

RL-7090





## PRINICIPAL DISPLAY PANEL - 10 mL Syringe Carton

10 mL

NDC 0409-1775-40

Infant

25%

DEXTROSE

Injection, USP

2.5 g/10 mL

(250 mg/mL)

Ansy<sup>TM</sup>

Unit of Use Syringe

Rx only

Hospira


LOT #####AA

EXP DMMYYYYY

◀ PRESS AND PULL TO OPEN ▶

**Use Aseptic Technique**

1. Remove luer cover.



2. Hold plunger and push barrel forward to relieve any resistance that may be present.



3. Pull the barrel down until air is expelled from the syringe.



**Infant**  
**25% DEXTROSE Injection, USP**  
**2.5 g/10 mL**  
**(250 mg/mL)**



LOT #####AA  
EXP DMMYYYY

**Infant**  
**25% DEXTROSE**  
**Injection, USP**  
**2.5 g/10 mL**  
**(250 mg/mL)**

10 mL NDC 0409-1775-40

10 mL NDC 0409-1775-40

**Infant**  
**25%**  
**DEXTROSE**  
**Injection, USP**  
**2.5 g/10 mL**  
**(250 mg/mL)**

**Ansyrr™**

**Unit of Use Syringe**

**Rx only**




LOT #####AA

Single-dose unit. Discard unused portion. For intravenous use. **Usual dosage:** See insert. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Each mL contains dextrose, hydrous 250 mg. May contain HCl and NaOH for pH adjustment. 1.39 mOsmol/mL (calc.). pH is 4.5 (3.2 to 6.5). Medication and fluid path are sterile and nonpyrogenic if cap is in place and package is intact.

**OSE Injection, USP**  
**(250 mg/mL)**





## DEXTROSE

dextrose monohydrate injection, solution

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0409-1775
Route of Administration	INTRAVENOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	250 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0409-1775-10	10 in 1 PACKAGE	02/22/2006	
1		1 in 1 CARTON		
1	NDC:0409-1775-40	10 mL in 1 SYRINGE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA019445	02/22/2006	

**Labeler** - Hospira, Inc. (141588017)

## Establishment

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		827731089	ANALYSIS(0409-1775)

## Establishment

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		093132819	ANALYSIS(0409-1775) , MANUFACTURE(0409-1775) , PACK(0409-1775) , LABEL(0409-1775)

## Establishment

Name	Address	ID/FEI	Business Operations
Roquette America, Inc.		627984446	API MANUFACTURE(0409-1775)

Revised: 8/2025

Hospira, Inc.